Applied nutritional investigationRandomized clinical trial: Effect of Lactobacillus plantarum 299 v on symptoms of irritable bowel syndrome
Section snippets
Background
Multiple clinical trials within the past decade have aimed to study the safety and efficacy of various probiotic strains in treating patients with irritable bowel syndrome (IBS). These trials provide guidance to health care professionals as they strive to treat patients suffering with IBS. Both positive and negative trial results provide a way forward and assist in the decision-making process. Health care workers are assailed with advertisements, representative details, patient expectations,
Participants
The present study was performed as a double-blind, placebo-controlled trial. Patients were recruited at a private gastroenterology clinic in Port Elizabeth, South Africa between January 2011 and April 2013. They were screened and recruited according to the study inclusion criteria and their willingness to participate. Constipation-predominant IBS (C-IBS) and diarrhea-predominant IBS (D-IBS) were included; the mixed type of IBS was excluded. Only C-IBS, D-IBS, and a placebo group were included
Results
The flow chart of the study is given in Figure 1. Eighty-one patients met the inclusion criteria, passed the run-in period, and were randomized. Fifty-four (66%) patients were randomized to receive L. plantarum 299 v and 27 (33%) the placebo; ratio of 2:1. Of the 54 patients randomized to receive the L. plantarum 299 v (50%, n = 27, were C-IBS and the other half, n = 27, D-IBS), the placebo was also equally distributed among D-IBS and C-IBS participants. The results are presented as the study
Discussion
The aim of this study was to conduct an appropriately well-designed randomized, double-blind, placebo-controlled clinical trial with L. plantarum 299 v and to determine its efficacy in IBS. No significant beneficial effects by the probiotic were seen on the severity of symptoms (abdominal pain) and quality of life.
To our knowledge this is the longest RCT reporting the effects of L. plantarum 299 v. Earlier interventions with L. plantarum 299 v had a 4-wk treatment phase [6], [7], [8], [28].
Conclusion
This study has demonstrated that an 8-wk treatment with L. plantarum 299 v did not provide relief for patients with moderate IBS symptoms over placebo and a very large placebo effect was demonstrated.
It is of the utmost importance that researchers strive to assess the efficacy of probiotics over placebo in treating patients with IBS and this means using more objective assessment methods. Probiotics may also prove to be a better treatment option in patients whose symptoms are on the lower end of
References (37)
- et al.
Alteration of intestinal microflora associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome
Am J Gastroenterol
(2000) - et al.
Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles
Gastroenterology
(2005) - et al.
Survival of Lactobacillus plantarum DSM 9843 (299 v), and effect on the short-chain fatty acid content of faeces after ingestion of a rose-hip drink fermented with oats
Int J Food Micro
(1998) - et al.
The effects of Lactobacillus strains and oat fiber on methotrexate-induced enterocolitis in rats
Gastroenterology
(1996) - et al.
Design of treatment trials for functional gastrointestinal disorders
Gastroenterology
(2006) - et al.
Defining the predictors of the placebo response in irritable bowel syndrome
Clin Gastroenterol Hepatol
(2005) - et al.
Design of treatment trials for functional gastrointestinal disorders
Gut
(1999) - et al.
The shortcomings of clinical trials assessing the efficacy of probiotics in irritable bowel syndrome
J Altern Complement Med
(2012) - et al.
The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review
Am J Gastroenterol
(2009) - et al.
Current and emerging therapies in irritable bowel syndrome: from pathophysiology to treatment
Trends Pharmacol Sci
(2010)
Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome
Am J Gastroenterol
A controlled double-blind, randomised study on the efficacy of Lactobacillus plantarum 299 V in patients with irritable bowel syndrome
Eur J Gastroenterol Hepatol
Effect of Lactobacillus plantarum 299 V on colonic fermentation and symptoms of irritable bowel syndrome
Dig Dis Sci
Treatment of irritable bowel syndrome with Lacteol-Fort: a randomised, double blind, crossover trial
Am J Gastroenterol
A randomised controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhea-predominant irritable bowel syndrome
Aliment Pharmacol Ther
A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-mo intervention
Aliment Pharmacol Ther
Effects of multispecies probiotc supplementation on intestinal microbiota in irritable bowel syndrome
Aliment Pharmacol Ther
Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilises intestinal microbiota
Aliment Pharmacol Ther
Cited by (57)
Efficacy and safety of probiotics in irritable bowel syndrome: A systematic review and meta-analysis
2024, Clinical Nutrition ESPENEffectiveness of probiotic/prebiotic/synbiotic treatments on anxiety: A systematic review and meta-analysis of randomized controlled trials
2023, Journal of Affective DisordersYogurt-derived Lactobacillus plantarum Q16 alleviated high-fat diet-induced non-alcoholic fatty liver disease in mice
2022, Food Science and Human WellnessCitation Excerpt :L. plantarum, one kind of lactic acid bacteria, also possesses probiotic functions and widely used in the functional foods [12]. Many strains belonging to L. plantarum have abilities to reduce cholesterol concentration [13], restore gastrointestinal diseases [14] and alleviate inflammatory bowel disease [15]. A recent study has revealed that L. plantarum ZJUFT17 alleviated glycerol monolaurate (GML)-induced metabolic syndrome by reducing body weight, improving serum lipid profile and suppressing low-grade inflammation [12].
Strain-specific and outcome-specific efficacy of probiotics for the treatment of irritable bowel syndrome: A systematic review and meta-analysis
2021, eClinicalMedicineCitation Excerpt :Of the 87 RCTs on IBS, 45 RCT (50 treatment arms) were then excluded, as there was only one RCT/type (Supplementary appendix, Table 1). As a result, 42 RCTs (45 treatment arms) were included in the systematic review (N = 3856) [18–59]. For the meta-analysis, two RCTs testing E. coli Nissle 1917 were excluded [27,28] as no common IBS outcome measurement was used.
AGA Technical Review on the Role of Probiotics in the Management of Gastrointestinal Disorders
2020, GastroenterologyCitation Excerpt :The Technical Review Panel did not identify a previously published systematic review that assessed the efficacy of probiotics for both children and adults with IBS; thus, we conducted a review of the literature from database inception through December 2018. The team screened 1617 titles and abstracts, assessed 216 full-text articles, and included 55 references119–173 in this review (Figure 6). These studies analyzed a total of 5301 patients (probiotics, n = 2768; placebo, n = 2533).
A systematic review and meta-analysis of diet and nutrient intake in adults with irritable bowel syndrome
2024, Neurogastroenterology and Motility
This study was funded in part by Nestle Nutrition Institute Africa and the South African National Research Foundation, gun number 2075266. CS, RB, EF, JV, and SR designed the research. CS and EF performed the research. CS analyzed the data. All authors helped draft the article. The authors declare they have no competing interests.